港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

同源康医药-B

15.410

-0.230-1.47%

成交量：514.25万

成交额：8,064.09万

市值：58.56亿

市盈率：-12.34

高：16.060

开：15.670

低：15.360

收：15.640

52周最高：56.550

52周最低：13.000

股本：3.80亿

香港流通股本：3.75亿

量比：0.25

换手率：1.37%

股息：- -

股息率：- -

每股收益(LYR):-1.249

净资产收益率：--

总资产收益率：-28.86%

市净率：11.46

市盈率(LYR):-12.34

市销率: 50221.99

数据加载中...

总览公司新闻公告

同源康医药-B年度亏损3.88亿元现金储备4.60亿元

格隆汇资讯

同源康医药-B(02410)：丁兆辞任非执行董事

同源康医药-B(02410)公布2024年业绩研发成本约2.35亿元同比收窄5.5%

同源康医药-B03月26日获主力加仓449万元

同源康医药-B03月24日获主力加仓1348万元

同源康医药-B03月21日获主力加仓1245万元

同源康医药-B03月20日主力净流入495万元散户资金抛售

同源康医药-B03月19日主力净流出71万元散户资金买入

同源康医药-B03月13日遭主力抛售85万元

同源康医药-B盘中异动股价大跌5.09%报30.750港元

同源康医药-B盘中异动急速下跌5.20%报33.700港元

“头对头”击败阿斯利康，同源康医药选择的小众赛道，尚无专属获批药物

“头对头”击败肺癌药物明星品种？同源康医药早盘一度涨超50%

关键临床数据达到研究预期，同源康医药-B(02410)展现高值潜力

同源康医药(02410)关键临床达预期股价早盘一度大涨50.65%

港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期

深交所发布关于深港通下的港股通标的证券名单调整的公告

深交所网站

同源康医药(02410)：TY-9591的关键II期临床试验研究者数据显示达到研究预期

智通港股早知道 | 港股今年日均成交额超2000亿港元 3月组件排产提升显著

【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02410/news?page=7"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02410","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"同源康医药-B","latestPrice":15.41,"timestamp":1756195697231,"preClose":15.64,"halted":0,"volume":5142500,"delay":0,"floatShares":375000000,"shares":380000000,"eps":-1.2489521363767515,"marketStatus":"已收盘","change":-0.23,"latestTime":"08-26 16:08:17","open":15.67,"high":16.06,"low":15.36,"amount":80640865,"amplitude":0.044757,"askPrice":15.42,"askSize":6500,"bidPrice":15.41,"bidSize":41000,"shortable":3,"etf":0,"ttmEps":-1.2489521363767515,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1756258200000},"marketStatusCode":5,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":15.64,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":0.249602,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","floatShares":375000000,"roa":"-28.86%","roe":"--","lyrEps":-1.248952,"volumeRatio":0.249602,"shares":380000000,"dividePrice":0,"high":16.06,"amplitude":0.044757,"preClose":15.64,"low":15.36,"week52Low":13,"pbRate":"11.46","psRate":"50221.99","week52High":56.55,"institutionHeld":0,"latestPrice":15.41,"committee":0.726316,"eps":-1.2489521363767515,"divideRate":0,"volume":5142500,"delay":0,"ttmEps":-1.2489521363767515,"open":15.67,"prevYearClose":47.15,"prevWeekClose":15.73,"prevMonthClose":20.3,"prevQuarterClose":21.7,"fiveDayClose":18.84,"twentyDayClose":21.35,"sixtyDayClose":25.2,"earningDate":1756569600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02410\",params:#limit:5,,,undefined,":[{"date":"2025-08-31","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756603800000,"name":null,"time":"","dateTimestamp":1756569600000,"actualEps":null},{"date":"2025-03-27","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743039000000,"name":null,"time":"","dateTimestamp":1743004800000,"actualEps":null},{"date":"2024-08-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724981400000,"name":null,"time":"","dateTimestamp":1724947200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02410\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02410\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1747584000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02410\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02410","date":"2025-08-25","current":-13.354956,"percent":0.976,"low":-45.171338,"twenty":-25.949863,"median":-22.318331,"eighty":-16.676594,"high":-10.104382,"avg":-22.494898,"sd":6.666208,"marketCap":5944229393},"quantilePoints":[{"date":"2024-08-23","current":-18.036629,"twenty":-16.647141,"median":-14.72623,"eighty":-12.008468,"marketCap":8010053668},{"date":"2024-08-30","current":-17.916348,"twenty":-18.108709,"median":-17.490261,"eighty":-14.277882,"marketCap":8010053668},{"date":"2024-09-06","current":-22.38992,"twenty":-20.387629,"median":-17.957821,"eighty":-15.985061,"marketCap":10531737231},{"date":"2024-09-13","current":-25.215246,"twenty":-24.52304,"median":-18.767123,"eighty":-16.911292,"marketCap":11829662594},{"date":"2024-09-20","current":-22.432724,"twenty":-24.518581,"median":-20.496807,"eighty":-17.208183,"marketCap":10587362603},{"date":"2024-09-27","current":-24.719835,"twenty":-24.497927,"median":-22.38992,"eighty":-17.671485,"marketCap":11736953639},{"date":"2024-10-04","current":-24.95032,"twenty":-24.87878,"median":-23.321155,"eighty":-17.932937,"marketCap":11792579012},{"date":"2024-10-10","current":-25.38933,"twenty":-24.941363,"median":-23.362473,"eighty":-17.973583,"marketCap":11922371548},{"date":"2024-10-18","current":-26.355956,"twenty":-25.311733,"median":-23.798709,"eighty":-18.108709,"marketCap":12311749157},{"date":"2024-10-25","current":-24.571342,"twenty":-25.374683,"median":-24.122054,"eighty":-18.545067,"marketCap":11477368567},{"date":"2024-11-01","current":-18.445843,"twenty":-25.311733,"median":-23.998666,"eighty":-18.584118,"marketCap":8621932768},{"date":"2024-11-08","current":-20.323115,"twenty":-25.278482,"median":-23.623818,"eighty":-17.973583,"marketCap":9456313359},{"date":"2024-11-15","current":-19.45318,"twenty":-25.171449,"median":-23.425489,"eighty":-18.108709,"marketCap":8955685004},{"date":"2024-11-22","current":-24.620137,"twenty":-24.988066,"median":-23.362473,"eighty":-18.406793,"marketCap":11329034239},{"date":"2024-11-29","current":-31.047836,"twenty":-25.311733,"median":-23.554037,"eighty":-18.584118,"marketCap":14277178993},{"date":"2024-12-06","current":-34.758675,"twenty":-25.786797,"median":-23.737743,"eighty":-19.168188,"marketCap":15945940174},{"date":"2024-12-13","current":-35.961329,"twenty":-26.0415,"median":-24.070769,"eighty":-19.324298,"marketCap":16465110319},{"date":"2024-12-20","current":-44.500897,"twenty":-30.298107,"median":-24.44033,"eighty":-19.494791,"marketCap":20284719244},{"date":"2024-12-27","current":-43.273475,"twenty":-31.455257,"median":-24.553474,"eighty":-19.619623,"marketCap":19709923726},{"date":"2025-01-03","current":-39.042242,"twenty":-33.760908,"median":-24.669986,"eighty":-19.709581,"marketCap":17800119264},{"date":"2025-01-10","current":-16.73771,"twenty":-34.083555,"median":-24.719835,"eighty":-19.709581,"marketCap":7602134269},{"date":"2025-01-17","current":-16.071561,"twenty":-33.760908,"median":-24.553474,"eighty":-18.860667,"marketCap":7305465614},{"date":"2025-01-24","current":-20.268382,"twenty":-32.413923,"median":-24.349989,"eighty":-19.230133,"marketCap":9270895450},{"date":"2025-01-28","current":-18.549699,"twenty":-31.591026,"median":-24.122054,"eighty":-18.549699,"marketCap":8529223814},{"date":"2025-02-07","current":-17.965815,"twenty":-31.472067,"median":-23.871541,"eighty":-18.275892,"marketCap":8214013368},{"date":"2025-02-14","current":-19.878813,"twenty":-31.451054,"median":-23.623818,"eighty":-18.275892,"marketCap":9066935750},{"date":"2025-02-21","current":-25.066745,"twenty":-31.047836,"median":-23.789321,"eighty":-18.32609,"marketCap":11495910358},{"date":"2025-02-28","current":-26.244856,"twenty":-30.411824,"median":-23.765234,"eighty":-18.39703,"marketCap":11996538712},{"date":"2025-03-07","current":-24.725844,"twenty":-30.135297,"median":-23.927628,"eighty":-18.445843,"marketCap":11347576030},{"date":"2025-03-14","current":-23.101371,"twenty":-29.84324,"median":-23.977848,"eighty":-18.549699,"marketCap":10605904394},{"date":"2025-03-21","current":-22.868028,"twenty":-28.789228,"median":-23.789321,"eighty":-18.691799,"marketCap":10494653649},{"date":"2025-03-28","current":-28.703724,"twenty":-28.703724,"median":-23.977848,"eighty":-19.110968,"marketCap":13146129748},{"date":"2025-04-03","current":-29.204856,"twenty":-29.744706,"median":-24.122054,"eighty":-19.131966,"marketCap":12070705875},{"date":"2025-04-11","current":-24.387234,"twenty":-29.307899,"median":-24.067881,"eighty":-19.145106,"marketCap":10012567086},{"date":"2025-04-17","current":-24.599189,"twenty":-28.955479,"median":-24.067881,"eighty":-19.224594,"marketCap":10123817831},{"date":"2025-04-25","current":-24.758022,"twenty":-28.755026,"median":-24.236021,"eighty":-19.282593,"marketCap":10197984995},{"date":"2025-05-02","current":-30.859428,"twenty":-28.772127,"median":-24.368612,"eighty":-19.308976,"marketCap":12738210348},{"date":"2025-05-09","current":-26.222368,"twenty":-28.789228,"median":-24.487968,"eighty":-19.376573,"marketCap":11477368567},{"date":"2025-05-16","current":-19.875071,"twenty":-28.703724,"median":-24.44033,"eighty":-19.45318,"marketCap":8770267095},{"date":"2025-05-23","current":-18.391406,"twenty":-28.460584,"median":-24.320388,"eighty":-19.147078,"marketCap":8139846205},{"date":"2025-05-30","current":-16.767615,"twenty":-28.328721,"median":-24.116277,"eighty":-18.777931,"marketCap":7453799941},{"date":"2025-06-06","current":-19.720458,"twenty":-27.077703,"median":-23.93026,"eighty":-18.847277,"marketCap":8788808886},{"date":"2025-06-13","current":-16.18601,"twenty":-26.697665,"median":-23.850097,"eighty":-18.709822,"marketCap":7216465018},{"date":"2025-06-20","current":-14.05098,"twenty":-26.664525,"median":-23.778892,"eighty":-18.426653,"marketCap":6252291891},{"date":"2025-06-27","current":-16.3221,"twenty":-26.630078,"median":-23.66211,"eighty":-18.32609,"marketCap":7283215465},{"date":"2025-07-04","current":-17.493079,"twenty":-26.41078,"median":-23.623818,"eighty":-18.194509,"marketCap":7806093968},{"date":"2025-07-11","current":-16.487526,"twenty":-26.267076,"median":-23.430941,"eighty":-17.964216,"marketCap":7349965912},{"date":"2025-07-18","current":-15.867745,"twenty":-26.226866,"median":-23.321155,"eighty":-17.866761,"marketCap":7068130691},{"date":"2025-07-25","current":-16.407488,"twenty":-26.143659,"median":-23.070409,"eighty":-17.335488,"marketCap":7335132480},{"date":"2025-08-01","current":-14.539711,"twenty":-26.072617,"median":-22.868028,"eighty":-17.325642,"marketCap":6459959949},{"date":"2025-08-08","current":-15.316665,"twenty":-25.987382,"median":-22.563641,"eighty":-17.04089,"marketCap":6822181433},{"date":"2025-08-15","current":-17.450454,"twenty":-25.968574,"median":-22.406203,"eighty":-16.915178,"marketCap":7760944003},{"date":"2025-08-22","current":-13.484776,"twenty":-25.95357,"median":-22.354126,"eighty":-16.718364,"marketCap":5978435317},{"date":"2025-08-25","current":-13.354956,"twenty":-25.949863,"median":-22.318331,"eighty":-16.676594,"marketCap":5944229393}],"updateTime":1756186960503},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02410\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522307117","title":"同源康医药-B年度亏损3.88亿元  现金储备4.60亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522307117","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522307117?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 22:19","pubTimestamp":1743085176,"startTime":"0","endTime":"0","summary":"格隆汇3月27日丨同源康医药-B公布年度业绩，集团的收入从截至2023年12月31日止年度的人民币0元增加至截至2024年12月31日止年度的人民币10.7万元，主要是研发服务收入增加所致。报告期间的亏损由截至2023年12月31日止年度的人民币3.83亿元增加1.2%至截至2024年12月31日止年度的人民币3.88亿元。现金及银行结余较于2023年12月31日的人民币1.87亿元增加146.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032722194097256236&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032722194097256236&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","02410","BK1161","BK1574"],"gpt_icon":0},{"id":"2522304757","title":"同源康医药-B(02410)：丁兆辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304757","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304757?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 22:10","pubTimestamp":1743084613,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)公布，丁兆博士已提出辞任公司非执行董事，自2025 年3月27日起生效，以投放更多时间从事其他业务承担。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1269454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","02410","BK1161","159938","BK1574","BK1515"],"gpt_icon":0},{"id":"2522734304","title":"同源康医药-B(02410)公布2024年业绩 研发成本约2.35亿元 同比收窄5.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522734304","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522734304?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 22:05","pubTimestamp":1743084319,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 公布2024年业绩，收入10.7万元，研发成本约2.35亿元，同比收窄5.5%。公司拥有人应占亏损约3.87亿元。公告称，收入从0到10.7万元主要是研发服务收入增加所致。研发成本减少主要归因于临床前研发支出的减少。自2017年成立以来，公司已建立由12款候选药物组成的管线，包括核心产品TY-9591、七款临床阶段产品及四款临床前阶段或早期临床开发阶段产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1269441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","09939","BK1574","159938","02410"],"gpt_icon":0},{"id":"2522845761","title":"同源康医药-B03月26日获主力加仓449万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522845761","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522845761?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 16:15","pubTimestamp":1742976928,"startTime":"0","endTime":"0","summary":"03月26日, 同源康医药-B股价涨5.43%，报收33.00元，成交金额4723万元，换手率0.42%，振幅11.02%，量比0.84。同源康医药-B今日主力资金净流入449万元，连续5日净流入，上一交易日主力净流入300万元。该股近5个交易日上涨22.71%，主力资金累计净流入3839万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入7241万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250326165301a6a478c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250326165301a6a478c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","09939","02410","BK1161","BK1574"],"gpt_icon":0},{"id":"2521797154","title":"同源康医药-B03月24日获主力加仓1348万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2521797154","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521797154?lang=zh_cn&edition=fundamental","pubTime":"2025-03-24 16:17","pubTimestamp":1742804221,"startTime":"0","endTime":"0","summary":"03月24日, 同源康医药-B股价涨12.90%，报收31.95元，成交金额8920万元，换手率0.81%，振幅17.84%，量比2.60。同源康医药-B今日主力资金净流入1348万元，连续3日净流入，上一交易日主力净流入1245万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为33.33%，平均涨幅为19.29%。该股近5个交易日上涨20.11%，主力资金累计净流入3018万元；近20日主力资金累计净流入6917万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250324170116a6a1d9e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250324170116a6a1d9e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","09939","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2521215470","title":"同源康医药-B03月21日获主力加仓1245万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2521215470","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521215470?lang=zh_cn&edition=fundamental","pubTime":"2025-03-21 16:17","pubTimestamp":1742545039,"startTime":"0","endTime":"0","summary":"03月21日, 同源康医药-B股价涨0.18%，报收28.30元，成交金额5230万元，换手率0.51%，振幅17.52%，量比2.12。同源康医药-B今日主力资金净流入1245万元，上一交易日主力净流入495万元。该股近5个交易日下跌2.45%，主力资金累计净流入1564万元；近20日主力资金累计净流入5631万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321170906a69eb0dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321170906a69eb0dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","BK1574","02410","09939"],"gpt_icon":0},{"id":"2520438795","title":"同源康医药-B03月20日主力净流入495万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2520438795","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520438795?lang=zh_cn&edition=fundamental","pubTime":"2025-03-20 16:16","pubTimestamp":1742458616,"startTime":"0","endTime":"0","summary":"03月20日, 同源康医药-B股价涨7.82%，报收28.25元，成交金额6724万元，换手率0.66%，振幅11.26%，量比3.78。同源康医药-B今日主力资金净流入495万元，上一交易日主力净流出71万元。该股近5个交易日上涨1.07%，主力资金累计净流入319万元；近20日主力资金累计净流入4386万元，其中净流入天数为10日。该股主力净额占比0.05%，港股市场排名121/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250320165755a43b0eb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250320165755a43b0eb0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","02410","BK1574","09939"],"gpt_icon":0},{"id":"2520297132","title":"同源康医药-B03月19日主力净流出71万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2520297132","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520297132?lang=zh_cn&edition=fundamental","pubTime":"2025-03-19 16:17","pubTimestamp":1742372222,"startTime":"0","endTime":"0","summary":"03月19日, 同源康医药-B股价跌3.68%，报收26.20元，成交金额982万元，换手率0.10%，振幅5.51%，量比0.47。同源康医药-B今日主力资金净流出71万元，上一交易日主力净流出0万元。该股近5个交易日下跌14.03%，主力资金累计净流出261万元；近20日主力资金累计净流入3891万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250319165948a43977c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250319165948a43977c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","BK1515","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2519887900","title":"同源康医药-B03月13日遭主力抛售85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887900?lang=zh_cn&edition=fundamental","pubTime":"2025-03-13 16:44","pubTimestamp":1741855479,"startTime":"0","endTime":"0","summary":"03月13日, 同源康医药-B股价跌8.65%，报收28.00元，成交金额3482万元，换手率0.33%，振幅12.07%，量比0.71。同源康医药-B今日主力资金净流出85万元，上一交易日主力净流出186万元。该股近5个交易日下跌4.91%，主力资金累计净流入2474万元；近20日主力资金累计净流入4066万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250313180539ab63bf5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250313180539ab63bf5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02410","09939","BK1515"],"gpt_icon":0},{"id":"2518164087","title":"同源康医药-B盘中异动 股价大跌5.09%报30.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518164087","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518164087?lang=zh_cn&edition=fundamental","pubTime":"2025-03-12 10:37","pubTimestamp":1741747079,"startTime":"0","endTime":"0","summary":"2025年03月12日早盘10时37分，同源康医药-B股票出现异动，股价大幅跳水5.09%。截至发稿，该股报30.750港元/股，成交量31.95万股，换手率0.09%，振幅9.10%。资金方面，该股资金流入110.233万港元，流出667.553万港元。同源康医药-B股票所在的生物技术行业中，整体跌幅为0.82%。同源康医药-B公司简介：浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250312103759ab5fb518&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250312103759ab5fb518&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09939","02410","BK1515"],"gpt_icon":0},{"id":"2518340927","title":"同源康医药-B盘中异动 急速下跌5.20%报33.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518340927","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518340927?lang=zh_cn&edition=fundamental","pubTime":"2025-03-11 09:33","pubTimestamp":1741656782,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘09时33分，同源康医药-B股票出现异动，股价快速下挫5.20%。截至发稿，该股报33.700港元/股，成交量3.25万股，换手率0.01%，振幅5.34%。资金方面，该股资金流入7.0875万港元，流出61.395万港元。同源康医药-B股票所在的生物技术行业中，整体跌幅为0.08%。同源康医药-B公司简介：浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。TY-2136b为自主研发、口服ROS1/NTRK抑制剂,用于治疗实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311093302abf4841b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311093302abf4841b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","BK1161","BK1515","09939","BK1574"],"gpt_icon":0},{"id":"2518980270","title":"“头对头”击败阿斯利康，同源康医药选择的小众赛道，尚无专属获批药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2518980270","media":"钛媒体","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518980270?lang=zh_cn&edition=fundamental","pubTime":"2025-03-11 00:00","pubTimestamp":1741622432,"startTime":"0","endTime":"0","summary":"同源康医药计划于近期提交卡达沙的NDA上市申请。根据同源康医药招股书介绍，卡达沙有两大单药研究方向：一是EGFR突变NSCLC脑转移，即癌细胞从其原发部位扩散到大脑，这一适应症目前尚无专属获批药物。目前，同源康医药公布了该实验的积极“头对头”数据。可见，同源康药业选择的小众赛道上，也不乏更多追赶者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031100003998a2bcda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031100003998a2bcda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","09939","BK1574","02410"],"gpt_icon":0},{"id":"2518527194","title":"“头对头”击败肺癌药物明星品种？同源康医药早盘一度涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518527194","media":"澎湃","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518527194?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 22:18","pubTimestamp":1741616326,"startTime":"0","endTime":"0","summary":"同源康医药 视觉中国 资料图3月10日，浙江同源康医药股份有限公司早盘最高涨超50%，收涨16.18%。同源康医药称，针对EGFR突变肺癌脑转移适应证，TY-9591是全球首个且唯一单药头对头奥希替尼临床研究中显示出显著优于奥希替尼的药物。“头对头”挑战这一重磅品种，同源康医药最新的积极数据自然引发全行业关注。官网资料显示，同源康医药成立于2017年11月，2024年8月在港股上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223049abf31290&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223049abf31290&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","09939","BK1574","02410"],"gpt_icon":0},{"id":"2518864264","title":"关键临床数据达到研究预期，同源康医药-B(02410)展现高值潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2518864264","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518864264?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 13:33","pubTimestamp":1741584788,"startTime":"0","endTime":"0","summary":"2017 年至 2024 年，中国肺癌脑转移的新患者人数从13.76 万增至17.14 万，预计肺癌脑转移的新患者人数于2033 年将接近22 万，展现国内该治疗市场的广阔前景。此次同源康医药-B公布的旗下 TY-9591 的关键 II 期临床试验研究者数据显示达到研究预期，将成为第三家在头对头试验中展现更优疗效的本土药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","BK1161","BK1574","159938","02410"],"gpt_icon":0},{"id":"2518252573","title":"同源康医药(02410)关键临床达预期 股价早盘一度大涨50.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518252573","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518252573?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 10:39","pubTimestamp":1741574389,"startTime":"0","endTime":"0","summary":"早盘股价表现亮眼，一度大幅抽升50.65%，至46.1港元，随后升幅有所回落，目前暂升26.47%，报38.7港元。此次备受关注的是公司自主研发的TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验。鉴于此次临床试验的积极结果，同源康医药计划在近期向国家药品监督管理局药品审评中心提交新药上市申请。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/NTRmYzVmNDdmYzg0MjRhYWE5NzljZDI3ZDUxMDYzNjE2NzY4MDQ=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTRmYzVmNDdmYzg0MjRhYWE5NzljZDI3ZDUxMDYzNjE2NzY4MDQ=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954677","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1515","09939","02410","BK1161","BK1574"],"gpt_icon":0},{"id":"2518255540","title":"港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2518255540","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518255540?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 09:34","pubTimestamp":1741570495,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B早盘一度涨超40%，截至发稿，涨36.93%，报41.9港元，成交额330万港元。消息面上，3月9日，同源康医药-B发布公告，公司自主研发的TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。公司计划于近期向国家药品监督管理局药品审评中心提交NDA上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03347","159938","TY","BK1161","BK1515","02410","BK1574","BK1583","09939","BK1576"],"gpt_icon":0},{"id":"2518258529","title":"深交所发布关于深港通下的港股通标的证券名单调整的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2518258529","media":"深交所网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518258529?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 08:58","pubTimestamp":1741568314,"startTime":"0","endTime":"0","summary":"因恒生综合大型股指数、中型股指数、小型股指数实施成份股定期调整,根据《深圳证券交易所深港通业务实施办法》的有关规定，港股通标的证券名单发生调整并自2025年03月10日起生效，相关调整信息如下：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310085053a269149e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310085053a269149e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02510","00659","02150","02562","02522","03939","09966","00743","02423","01119","BK1240","01600","02431","BK1582","02461","01468","02460","02105","02570","06623","06639","02410","01318","02232","02587","02407","03669","03650","00041","02171","00697","02411","BK1555","01799","00308","09869","03309","02507","00999","06660","01541","02121","06698","00095","02678","02506","02799","09959","01268","02487","02582","02586","02577","02432","09985","HSCEI","HSTECH","00410","01942"],"gpt_icon":0},{"id":"2518539642","title":"同源康医药(02410)：TY-9591的关键II期临床试验研究者数据显示达到研究预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2518539642","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518539642?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 08:54","pubTimestamp":1741568057,"startTime":"0","endTime":"0","summary":"金吾财讯 | 同源康医药 公告，公司自主研发的TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验根据研究者数据显示具有统计学显着意义和重大临床获益。主要研究终点颅内客观缓解率达到预期目的，TY-9591对比奥希替尼显示出统计学显着意义和临床意义的明显改善，无论在全人群还是在不同亚组人群中均具有明显统计学差异。公司计划于近期向国家药品监督管理局药品审评中心提交NDA 上市申请。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/MTczNjE1NTkxMzE1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/MTczNjE1NTkxMzE1OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954642","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09939","BK1576","159938","BK1574","BK1515","02410","BK1141","TY","BK1583","03347"],"gpt_icon":0},{"id":"2518923180","title":"智通港股早知道 | 港股今年日均成交额超2000亿港元 3月组件排产提升显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2518923180","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518923180?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 06:59","pubTimestamp":1741561142,"startTime":"0","endTime":"0","summary":"陈翊庭：港股今年以来日均成交额超2000亿港元港交所行政总裁陈翊庭9日表示，港股今年以来日均成交额超2000亿港元。陈翊庭说，港股成交额在过去一年也有很大进步，由2023年平均每日成交额大约1000亿港元升至去年的1320亿港元，今年暂时已突破2000亿港元。她说，今年2月，港股每日成交金额有3次突破4000亿港元，其中很大部分来自世界各地的投资者。涉及港股 港交所及优质券商板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","01208","BK1227","BK1574","YANG","02410","BK1592","BK1190","BK1161","BK4614","BK1594","HSTECH","HSCEI"],"gpt_icon":1},{"id":"2518684402","title":"【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518684402","media":"金融界","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518684402?lang=zh_cn&edition=fundamental","pubTime":"2025-03-09 19:12","pubTimestamp":1741518744,"startTime":"0","endTime":"0","summary":"同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/09191248615055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","TY","BK1141","159938","BK1515","09939","BK1583","03347","02410","BK1161","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":147,"code":"91000000","status":"200"}]}}